EGFR and lung carcinoma: A recent study demonstrated that PA-MSHA could directly induce G0-G1 cell cycle arrest of the cancer cells [32], suggesting the combination of PA-MSHA and gefitinib inhibits lung cancer cell proliferation through an EGFR independent pathway.